Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVOGet Rating) in a report released on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on the company. TheStreet raised Aptevo Therapeutics from a d rating to a c- rating in a research note on Friday, August 26th. Piper Sandler dropped their target price on Aptevo Therapeutics from $20.00 to $13.00 in a report on Friday, August 12th.

Aptevo Therapeutics Price Performance

NASDAQ APVO opened at $2.97 on Monday. The business has a fifty day simple moving average of $3.03 and a 200 day simple moving average of $3.71. Aptevo Therapeutics has a 12 month low of $2.67 and a 12 month high of $15.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.16 and a quick ratio of 3.16.

Hedge Funds Weigh In On Aptevo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APVO. Cantor Fitzgerald L. P. purchased a new stake in Aptevo Therapeutics during the third quarter valued at approximately $406,000. Citadel Advisors LLC purchased a new stake in Aptevo Therapeutics during the third quarter valued at approximately $51,000. Virtu Financial LLC raised its position in Aptevo Therapeutics by 122.6% during the third quarter. Virtu Financial LLC now owns 28,421 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 15,653 shares during the period. Renaissance Technologies LLC raised its position in Aptevo Therapeutics by 18.7% during the second quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 11,000 shares during the period. Finally, Vanguard Group Inc. raised its position in Aptevo Therapeutics by 7.3% during the first quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 16,337 shares during the period. 15.63% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

(Get Rating)

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.

Read More

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.